Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 98

1.

Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients.

Mukonzo JK, Kengo A, Kutesa B, Nanzigu S, Pohanka A, McHugh TD, Zumla A, Aklillu E.

Trans R Soc Trop Med Hyg. 2019 Dec 2. pii: trz108. doi: 10.1093/trstmh/trz108. [Epub ahead of print]

PMID:
31789383
2.

Pregnancy and CYP3A5 Genotype Affect Day 7 Plasma Lumefantrine Concentrations.

Mutagonda RF, Minzi OMS, Massawe SN, Asghar M, Färnert A, Kamuhabwa AAR, Aklillu E.

Drug Metab Dispos. 2019 Dec;47(12):1415-1424. doi: 10.1124/dmd.119.088062.

PMID:
31744845
3.

Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study.

Tadesse BT, Chala A, Mukonzo J, Chaka TE, Tadesse S, Makonnen E, Brumme ZL, Brumme CJ, Aklillu E.

Pathogens. 2019 Sep 24;8(4). pii: E161. doi: 10.3390/pathogens8040161.

4.

CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients.

Ahmed JH, Makonnen E, Fotoohi A, Aseffa A, Howe R, Aklillu E.

Cancers (Basel). 2019 Sep 12;11(9). pii: E1353. doi: 10.3390/cancers11091353.

5.

Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia.

Tadesse BT, Tsai O, Chala A, Chaka TE, Eromo T, Lapointe HR, Baraki B, Shahid A, Tadesse S, Makonnen E, Brumme ZL, Aklillu E, Brumme CJ.

Viruses. 2019 Sep 19;11(9). pii: E877. doi: 10.3390/v11090877.

6.

Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region.

Mikomangwa WP, Oms M, Aklillu E, Kamuhabwa AAR.

BMC Pregnancy Childbirth. 2019 Jul 8;19(1):236. doi: 10.1186/s12884-019-2397-1.

7.

CYP2J27 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients.

Ahmed JH, Makonnen E, Yimer G, Seifu D, Bekele A, Assefa M, Aseffa A, Howe R, Fotoohi A, Hassan M, Aklillu E.

Front Pharmacol. 2019 May 14;10:481. doi: 10.3389/fphar.2019.00481. eCollection 2019.

8.

Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals.

Mukonzo J, Aklillu E, Marconi V, Schinazi RF.

Int J Infect Dis. 2019 Jun;83:98-101. doi: 10.1016/j.ijid.2019.04.009. Epub 2019 Apr 13.

9.
10.

HIV and cART-Associated Dyslipidemia Among HIV-Infected Children.

Tadesse BT, Foster BA, Chala A, Chaka TE, Bizuayehu T, Ayalew F, H/Meskel G, Tadesse S, Jerene D, Makonnen E, Aklillu E.

J Clin Med. 2019 Mar 28;8(4). pii: E430. doi: 10.3390/jcm8040430.

11.

Vitamin D Status and Association of VDR Genetic Polymorphism to Risk of Breast Cancer in Ethiopia.

Ahmed JH, Makonnen E, Fotoohi A, Yimer G, Seifu D, Assefa M, Tigeneh W, Aseffa A, Howe R, Aklillu E.

Nutrients. 2019 Jan 29;11(2). pii: E289. doi: 10.3390/nu11020289.

12.

Conference report: pharmacogenomics in special populations at WCP2018.

Suarez-Kurtz G, Aklillu E, Saito Y, Somogyi AA.

Br J Clin Pharmacol. 2019 Mar;85(3):467-475. doi: 10.1111/bcp.13828. Epub 2019 Jan 24. Review.

PMID:
30537134
13.

Cigarette smoking and heavy coffee consumption affecting response to olanzapine: the role of genetic polymorphism.

Djordjevic N, Radmanovic B, Cukic J, Baskic D, Djukic-Dejanovic S, Milovanovic D, Aklillu E.

World J Biol Psychiatry. 2018 Dec 4:1-53. doi: 10.1080/15622975.2018.1548779. [Epub ahead of print]

PMID:
30513034
14.

Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.

Kitabi EN, Minzi OMS, Mugusi S, Sasi P, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E.

Sci Rep. 2018 Nov 5;8(1):16316. doi: 10.1038/s41598-018-34674-3.

15.

Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations.

Bedada W, de Andrés F, Engidawork E, Hussein J, LLerena A, Aklillu E.

Sci Rep. 2018 Aug 24;8(1):12726. doi: 10.1038/s41598-018-31191-1.

16.

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.

Mugusi S, Ngaimisi E, Janabi M, Mugusi F, Minzi O, Aris E, Bakari M, Bertilsson L, Burhenne J, Sandstrom E, Aklillu E.

Eur J Clin Pharmacol. 2018 Nov;74(11):1405-1415. doi: 10.1007/s00228-018-2499-0. Epub 2018 Jul 12.

17.

N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians.

Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, Djordjevic N.

Eur J Clin Pharmacol. 2018 Jul;74(7):903-911. doi: 10.1007/s00228-018-2448-y. Epub 2018 Mar 27.

18.

High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia.

Tadesse BT, Kinloch NN, Baraki B, Lapointe HR, Cobarrubias KD, Brockman MA, Brumme CJ, Foster BA, Jerene D, Makonnen E, Aklillu E, Brumme ZL.

Viruses. 2018 Feb 1;10(2). pii: E60. doi: 10.3390/v10020060.

19.

Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.

Mutagonda RF, Kamuhabwa AAR, Minzi OMS, Massawe SN, Asghar M, Homann MV, Färnert A, Aklillu E.

Malar J. 2017 Jul 3;16(1):267. doi: 10.1186/s12936-017-1914-9.

20.

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.

Habtewold A, Aklillu E, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Owen JS.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00207-17. doi: 10.1128/AAC.00207-17. Print 2017 Aug.

Supplemental Content

Loading ...
Support Center